News & Updates

The use of Janus kinase (JAK) inhibitors in the treatment of major autoimmune diseases appears to reduce the risk of age-related macular degeneration (AMD) for people above 40 years of age, according to a study.

Treatment with ixekizumab resulted in almost 90 percent of children with active juvenile psoriatic arthritis (JPsA) or enthesitis-related arthritis (ERA) achieving an ACR30* response by week 16, according to the ongoing COSPIRIT-JIA trial presented at EULAR 2024.

Patients with cirrhosis and nonvalvular atrial fibrillation (AF) who initiated rivaroxaban are more likely to experience major haemorrhage than those administered with apixaban, according to a study. However, the rates of ischaemic events and death are similar between the two treatment groups.